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Extracellular vesicles (EVs) are plasma membrane-bound fragments released from several cell types, including
mesenchymal stromal cells (MSCs), constitutively or under stimulation. EVs derived from MSCs and other cell
types transfer molecules (such as DNA, proteins/peptides, mRNA, microRNA, and lipids) and/or organelles with
reparative and anti-inflammatory properties to recipient cells. The paracrine anti-inflammatory effects promoted
by MSC-derived EVs have attracted significant interest in the regenerative medicine field, including for potential
use in lung injuries. In the present review, we describe the characteristics, biological activities, and mechanisms of action
of MSC-derived EVs. We also review the therapeutic potential of EVs as reported in relevant preclinical models of acute
and chronic respiratory diseases, such as pneumonia, acute respiratory distress syndrome, asthma, and pulmonary arterial
hypertension. Finally, we discuss possible approaches for potentiating the therapeutic effects of MSC-derived EVs so as to
enable use of this therapy in clinical practice.Background
In recent decades, the therapeutic potential and safety of
mesenchymal stromal cells (MSCs) has been studied in
the context of regeneration and immune modulation of
injured tissues [1]. Many studies have demonstrated that,
when systemically administered, MSCs are recruited to
sites of inflammation through still-incompletely under-
stood chemotactic mechanisms [2], stimulate endogenous
repair of injured tissues [3], and modulate immune
responses [4]. The beneficial effects of MSCs on tissue
repair and regeneration are based on their paracrine activ-
ity, characterized by the capacity to secrete growth factors,
cytokines, and chemokines, which orchestrate interactions
within the microenvironment and influence tissue regen-
eration. These factors can inhibit apoptosis, stimulate
proliferation, promote vascularization, and modulate the
immune response [5]. Remarkably, conditioned medium
collected from MSCs can convey many of these protective
effects, suggesting that soluble factors rather than cell–cell
contact are the major mechanism of MSC actions [6].* Correspondence: prmrocco@gmail.com
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of these paracrine effects are mediated by extracellular
vesicles (EVs) contained in the conditioned medium. EVs
are small, spherical membrane fragments including exo-
somes, microvesicle particles, and apoptotic bodies in
accordance with the recommendations of the Inter-
national Society for Extracellular Vesicles (ISEV) [7]. The
EVs are released by cells that are involved in cell-to-cell
communication and are capable of altering the fate and
phenotype of recipient cells [8]. The exosomes arise from
intracellular endosomes, while the microvesicles originate
directly from the plasma membrane. These particle types
are secreted from a wide range of different cell types,
including T and B lymphocytes, dendritic cells (DCs),
mast cells, platelets, and MSCs derived from different tis-
sues (bone marrow, placenta, as well as adipose and lung
tissues), and can also be isolated in vivo from body fluids
such as urine, serum, and bronchoalveolar lavage fluid
(BALF) [9, 10]. Nevertheless, the classification of EVs dif-
fers depending on their origin, size, and contents (Table 1).
Additionally, the number and nature of EVs may be
affected by gender, age, circadian rhythms, fasting state,
medication exposure, and physical activity [11]. However,
whether these different classes of EVs represent distinctis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Characterization of extracellular vesicles
Extracellular
vesicles
Origin Size Content Markers
Exosomes Multivesicular
bodies
50–150 nm Proteins, and lipids,
DNA, mRNA and miRNA
CD63, CD81, CD9, heat-shock proteins,
Alix, Tsg101, integrin, annexins and
MHC classes I and II
Microvesicles Plasma membrane 150–1000 nm Proteins, and lipids, DNA,
mRNA, miRNA and cell organelles.
Integrins, flotillins and tetraspanins
Apoptotic bodies Membrane of dying cells >1 μm DNA, noncoding RNAs and cell organelles Surface markers for macrophages
Alix ALG-2-interacting protein X, MHC major histocompatibility complex, miRNA microRNA, Tsg101 tumor susceptibility gene 101
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been used to characterize the different classes of EVs, in-
cluding size, ionic composition, sedimentation rate,
flotation density on a sucrose gradient, lipid composition,
protein cargo, and biogenesis pathway; however, most of
these parameters are neither definitive nor exclusive to
any specific class of EVs (Fig. 1) [7].Fig. 1 Schematic representation of EVs biogenesis. Vesicles bud directly from th
generated by inward budding of the limiting membrane of a subgroup of late
towards the cell periphery and, after fusion with the plasma membrane, r
MSC mesenchymal stromal cellExosomes range in size from 50 to 150 nm, have a
homogeneous shape, and are defined as a subtype of EVs
derived from specialized intracellular compartments, the
multivesicular bodies (MVBs) [12]. Exosomes are consti-
tutively released from cells, but their release is aug-
mented significantly following activation by soluble
agonists (cytokines, chemokines, and growth factors), ase plasma membrane, whereas exosomes originate from ILVs that are
endosomes called multivesicular bodies (MVBs). MVBs can be directed
elease their content into the extracellular space. miRNA microRNA,
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and shear stresses [13]. In order to form an exosome,
the limiting membrane of the MVBs buds inward, thus
forming intraluminal vesicles (ILVs), which then fuse
with the plasma membrane to release ILVs as exosomes.
This process is mediated by p53-regulated exocytosis,
which is dependent on cytoskeletal activation but inde-
pendent of cell calcium influx [14]. In contrast, microve-
sicles range from 150 to 1000 nm in size and are more
heterogeneous. They are released by budding of small
cytoplasmic protrusions, a process dependent on calpain,
cytoskeletal reorganization, and intracellular calcium
concentration. Calcium ions are responsible for the
asymmetric phospholipid distribution of the plasma
membrane that yields microvesicle formation [14].
Finally, there is another type of EVs, larger than 1 μm:
the apoptotic body, derived from dying cells. DNA, as a
residue of the nucleus, is frequently present within these
vesicles, as are noncoding RNAs and cell organelles [15].
The different EVs can be isolated from body fluids or
in vitro cultured cells by specific standardized protocols,
and characterized by differential ultracentrifugation,
ultrafiltration, and immunoprecipitation with the use of
antibody-loaded magnetic cell beads [16]. These proce-
dures are critical because all types of vesicles, as well as
membrane fragments, are normally present in the starting
material and can contaminate specific EVs preparations.
One major challenge in EVs research is therefore to
standardize methods for isolation and analysis. Addition-
ally, it is difficult to distinguish between exosomes and
microvesicles because of their overlapping characteristics
and the lack of discriminating markers [17]. Nevertheless,
among the many subtypes of EVs, exosomes have emerged
as physiologically relevant and powerful components of
the MSC secretome [18].
The content of EVs consists of proteins, lipids, and
nucleic acids; microvesicles and apoptotic bodies also
have organellar contents. Since the effects of EVs usually
depend on their cell of origin and may be influenced by
physiological stress or pathological conditions, they
could be used as biomarkers to diagnose, prognosticate,
or predict diseases and their natural history [14]. Many
reports have shown that the functions of EVs reflect, at
least in part, those of their originating cells; differences
between them occur because the EVs composition may
be modified, suggesting that preferential packaging or
exclusion of material occurs [19]. Information on the
protein, lipid, and RNA expressions of EVs is collected
in VESICLEPEDIA (http://www.microvesicles.org) [20],
while the exosomes of different cell types and organisms
are described in the ExoCarta database [21]. EVs play an
important role in intercellular communication and are
capable of modifying the activity of target cells through dir-
ect surface receptor interactions, receptor transfer betweencells, protein delivery to target cells, or horizontal transfer
of genetic information [22]. They are involved in cellular
processes such as angiogenesis modulation, cell prolifera-
tion, and immune regulation [23]. EVs are therefore par-
ticularly attractive for their therapeutic potential, especially
MSC-derived EVs, which appear to be an important tool to
harness the clinical benefits of MSC therapy while using
cell-free strategies based on the MSC secretome. These
strategies may reduce the risks associated with engraftment
of MSCs, such as possible immune reactions against MSCs
and development of ectopic tissue. Since EVs carry a wide
array of signals, several studies have been performed evalu-
ating their implication in animal models of organ injury,
including lung diseases. Nonetheless, comprehensive
insight regarding the full scope of molecules packaged in
MSC-derived EVs and their role in tissue regeneration has
yet to be gained, and additional studies are needed to pro-
vide greater detail [9, 23].
Characteristics of MSC-derived EVs
MSC-derived EVs express surface molecules, such as
CD29, CD73, CD44, and CD105, which are characteristic
of their cells of origin. Among the MSC-derived EVs, the
exosomes are those best characterized. Exosomes are
known to conserve a set of proteins, including tetraspa-
nins, involved in cell targeting (CD63, CD81, and CD9);
heat-shock proteins Hsp60, Hsp70, and Hsp90 [24]; ALG-
2-interacting protein X (Alix) and tumor susceptibility
gene 101 (Tsg101), which are involved in their biogenesis
from MVBs; integrins and annexins, which are important
for transport and fusion [20]; and major histocompatibility
complex classes I and II [25]. Microvesicles lack proteins
of the endocytic pathway, but are rich in cholesterol and
lipid raft-associated proteins, such as integrins and flotil-
lins. Although tetraspanins are commonly used as unique
markers for exosomes, they can be detected in microvesi-
cles in some cases [26]. Several studies have been con-
ducted evaluating the potential role of MSC-derived
EVs in physiological and pathological conditions and
their possible applications in the therapy of different
diseases [12, 15]; however, few studies have evaluated
the RNA and protein content of these vesicles.
MSC-derived EVs are enriched by distinct classes of
RNAs that could be transferred to target cells and
translated into proteins, resulting in an alteration of
target cell behavior [27]. In particular, MSC-derived
EVs contain transcripts involved in control of transcrip-
tion (transcription factor CP2, clock homolog), cell pro-
liferation (retinoblastoma-like 1, small ubiquitin-related
modifier 1), and immune regulation (interleukin 1
receptor antagonist) [27]. Additionally, MSC-derived
EVs contain noncoding RNA, microRNAs (miRNAs)
that mediate posttranscriptional control of gene expres-
sion and, as such, modulate survival and metabolic
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present both in EVs and/or in their cells of origin [9].
The miRNAs detected in MSC-derived EVs are usually
related to development, cell survival, and differenti-
ation, while some MSC-derived EVs-enriched miRNAs
are more closely associated with regulation of the
immune system [9]. Comprehensive information on the
complete RNA content of MSC-derived EVs is not cur-
rently available, however, and whether adult MSCs from
different sources share similar RNA repertoires remains
unknown. A recent study compared the RNA profile of
exosomes released by adult MSCs from two different
sources: adipose-derived MSCs (ASCs) and bone marrow-
derived MSCs (BM-MSCs). Despite substantial similarity
between the most represented RNAs in the ASC and BM-
MSC exosomes, their relative proportions are different [29].
Proteome analysis may be equally important.
Characterization of the content of BM-MSC-derived
EVs identified several proteins, among which are
mediators controlling self-renewal and differentiation.
Interestingly, this analysis revealed a number of sur-
face markers, such as platelet-derived growth factor
receptor, epidermal growth factor receptor, and plas-
minogen activator, urokinase receptor; signaling mole-
cules of the RAS-mitogen-activated protein kinase,
Rho GTPase, and Cell division control protein 42
pathways; cell adhesion molecules; and additional
MSC antigens [30], supporting a possible role for such
vesicles in tissue repair. Treatment of cell-derived EVs
with specific growth factors can change the phenotype
and protein content of these vesicles; for example,
ASCs treated with platelet-derived growth factor have
been shown to produce EVs with enhanced angiogenic
activity [31]. This wide distribution of biological activ-
ities gives MSC-derived EVs the potential to elicit
diverse cellular responses and interact with many cell
types.
Mechanisms of action and biological activities of
EVs
EVs may interact with recipient cells by different
mechanisms: interactions at the cell surface, internal-
ization into endocytic compartments, and fusion with
plasma membranes (Fig. 1) [32]. The efficiency of EVs
uptake has been observed to correlate directly with
intracellular and microenvironmental acidity [33]. Fol-
lowing ligand interaction, EVs may deliver their contents
to the recipient cell that reprogrammed them. Recently,
EVs from stem cells were demonstrated to shuttle a
cysteine-selective transport channel (cystinosin) that re-
stores function in mutant target cells [34]. EVs may also
mediate the horizontal transfer of genetic information,
such as subsets of mRNA and miRNA, from the cell of
origin, thereby inducing alterations in the phenotypeand behavior of recipient cells by different pathways
[35]. In this line, EVs produced by murine embryonic
stem cells may reprogram hematopoietic progenitors
by delivering not only proteins but also mRNA for
several pluripotent transcription factors [36], whereas
pretreatment of these EVs with RNase inhibited the
observed biological effects, thus suggesting the contri-
bution of EVs-derived mRNA [36]. Stem cells may
therefore modulate their biological effects by deliver-
ing genetic information and altering the gene expres-
sion of target cells. Interestingly, the exchange of
genetic information may be bidirectional: from injured
cells to bone marrow-derived or resident stem cells;
or from stem cells to injured cells. In this context,
Dooner et al. [37] reported that bone marrow stem
cells cocultured with injured lung cells expressed
genes for lung-specific proteins, such as surfactant B
and C, and Clara cell-specific proteins, which may be
attributed to the transfer of lung-specific mRNAs to
bone marrow cells via EVs released from the injured
lung cells.
Additionally, EVs derived from injured and immune
cells may induce stem cell recruitment and differenti-
ation of resident stem cells present in several organs
during adulthood, thus contributing to physiologic tissue
repair [13]. Nevertheless, depending on their cells of
origin, EVs can exert immunostimulatory or immuno-
suppressive effects [38]. Alveolar macrophages infected
with mycobacteria release EVs containing pathogen-
derived proinflammatory molecules and secrete Hsp70,
which activates the nuclear factor-κB pathway by stimu-
lating toll-like receptors (TLRs) [15], leading to the
secretion of proinflammatory cytokines [14, 24]. On the
other hand, EVs secreted by DCs are able to induce
humoral responses against antigens processed by DCs be-
fore EVs purification, yielding strong protection against in-
fection [39]. EVs may also modulate the function of target
cells. For instance, EVs derived from lipopolysaccharide-
activated monocytes induce apoptosis in target cells
through transfer of caspase-1 [40]. Furthermore, prote-
omic analysis of damaged tissues usually reveals they are
depleted of many rate-limiting ATP-generating enzymes,
and are thus unable to utilize the restored oxygen supply
to produce ATP. This depletion could be supplemented
by the proteome of MSC-derived exosomes, which has a
cargo rich in enzymatically active glycolytic enzymes and
other ATP-generating enzymes, such as adenylate kin-
ase and nucleoside-diphosphate kinase [41].
However, MSC-derived EVs have received more em-
phasis in the literature and have been most widely stud-
ied. In this line, EVs released from human MSCs have
been shown to contain ribonucleoproteins involved in
the intracellular trafficking of RNA and selected pat-
terns of miRNA, suggesting dynamic regulation and
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ment, regulation, regeneration, and cell differentiation,
which contribute to recovery processes after injury of
adult tissues (Fig. 2) [42]. Indeed, MSC-derived EVs
exert an important inhibition in the differentiation and
activation of T cells and their interferon-gamma (IFN-γ)
release in vitro, as well as stimulating the secretion of
anti-inflammatory cytokines (interleukin (IL)-10 and
transforming growth factor beta (TGF-β)) and generation
of regulatory T cells [43], suggesting that MSC-derived
exosomes are relevant immunomodulatory therapeutic
agents (Fig. 2). Additionally, treatment with MSC-derived
EVs activates an M2 macrophage-like phenotype in the
lung parenchyma, which is known to promote tissue
repair and limit injury [44].
The immunomodulatory effects of BM-MSCs and
derived EVs have been analyzed in vitro. BM-MSCs and
their EVs exhibit similar inhibitory activity against B-cell
proliferation, but EVs display less inhibitory activity on
differentiation and antibody release of B cells compared
with BM-MSCs. Moreover, BM-MSCs are more efficient
than EVs at inhibiting T-cell proliferation. In one study,
incubation of both T cells and B cells with EVs led to a
decrease in granulocyte–macrophage colony-stimulating
factor and IFN-γ and an increase in IL-10 and TGF-β
compared with BM-MSCs [45].Fig. 2 Scheme illustrating extracellular vesicle (EV) function related to tissu
miRNA) from MSCs or resident stem cells contributes to tissue repair. IFN in
factor beta, Treg regulatory T cellTherapeutic potential of MSC-derived EVs in lung
diseases
MSC-derived EVs have shown to be a promising therapy
enabling tissue repair and wound healing. The effects of
MSC-derived EVs can be potentiated under some condi-
tions, such as exposure to hypoxia and coculture with
animal or human serum obtained in pathologic condi-
tions. These methods may induce the release and po-
tentiate the effects of these EVs due to stimulation and
the presence of cytokines and chemotactic and growth
factors, which not only increase EVs release but may also
modify their content, leading to enhancement of benefi-
cial effects.
EVs are also important vehicles for drug delivery
because of their lipid bilayer and aqueous core, since
they can carry both lipophilic and hydrophilic drugs
[46]. Furthermore, EVs present several advantages for
this purpose, such as: presence of protein and genetic
materials, which enables active loading of biological
material; high tolerability in the body due to the pres-
ence of inhibitors of complement and phagocytosis [30];
protection against degradative enzymes or chemicals;
and ability to cross the plasma membrane to deliver
their cargo to target cells [9, 47] and home to target tis-
sues [9, 46]. Electroporation [48] and viral packaging
strategies [49] have been used to load therapeuticallye repair. The exchange of proteins and genetic information (mRNA and
terferon, IL interleukin, miRNA microRNA, TGFβ transforming growth
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small interfering RNA (siRNA)) into EVs [48, 49].
While a predominant mechanism of MSCs in tissue
repair through paracrine activity has already been sug-
gested, some studies are being carried out to better under-
stand the mechanisms associated with the beneficial
effects of MSC-derived EVs in lung diseases, such as
asthma, pulmonary arterial hypertension (PAH), acute
respiratory distress syndrome (ARDS), and pneumonia
(Table 2), and how they can be potentiated for translation
to clinical practice.
Asthma
Asthma is a chronic inflammatory disease characterized
by airway constriction and inflammation, which may
lead to structural changes in the airways, often in
response to allergens, infections, and air pollutants [50].
Even though several therapeutic strategies are currently
available to reduce airway inflammation, no treatment
has so far been able to hasten repair of the damaged
lung [51]. In this line, some studies reported that MSCs
reduced lung inflammation and remodeling in experi-
mental allergic asthma [52–54].Table 2 Effects of extracellular vesicles in lung diseases
Study Model Origin
Admyre
et al., 2008 [55]
Allergic inflammation Mast cell-derived EVs
Bakouboula
et al., 2008 [63]










Endotoxin-induced ARDS CM from MSC
Lee et al.,
2012 [65]
Hypoxia-induced PAH MSC-derived EVs
Torregrosa et al., 2012
[60]
Coculture of BECs with
BALF EVs from asthmatic
patients

























MSC and MSC-derived EV
ARDS acute respiratory distress syndrome, BALF bronchoalveolar lavage fluid, BEC b
extracellular vesicle, hMSC human mesenchymal stem cell, IGF-1 insulin-like growth
cell, mMSC mouse mesenchymal stem cell, PAH pulmonary arterial hypertension, ThEVs are released from several cells that are involved in
allergies, including mast cells, DCs, T cells, and bronchial
epithelial cells (BECs) in the lungs. For example, mast
cell-derived EVs induce DC maturation, and DC-derived
EVs can transport allergens and activate allergen-specific
T-helper (Th) type 2 cells [55]. Among several potential
mechanisms, BECs exposed to compressive stress – thus
simulating the bronchoconstriction seen in asthma – pro-
duce EVs bearing tissue factor which may participate in
promotion of subepithelial fibrosis and angiogenesis [56].
In short, available data indicate the potential contributions
of BEC-derived EVs to the pathogenesis of asthma. Add-
itionally, these findings may lead to the development of
future treatments for asthma patients that target the
inhibition of EVs secretion by these cells.
Several phenotypic and functional alterations have been
observed in BALF EVs from asthmatics compared with
healthy patients. These include higher expression of
CD36, which has been implicated in bacterial recognition
and may play a role in asthma exacerbations in response
to bacterial infections [57], and that the EVs contain miR-
NAs, critical regulators of specific pathogenic events [58]
which may act as biomarkers of lung diseases, such as theEffects




Increase in EVs release is directly related to PAH severity
ice Inhibition of IgE response, Th2 cytokine production, and
airway inflammation
Increase in secretion of exosomes by MSCs and M2
macrophages, in part via IGF-1
Reduced right ventricular systolic pressure and right
ventricular hypertrophy
tic Increased leukotriene and IL-8 release
-derived
nduced
Increased right ventricular mass and pulmonary
vascular wall thickness
Reduction in extravascular lung water, total protein
levels in BALF, edema, neutrophil infiltration, associated
with increased KGF expression
More significant reduction of airway hyperresponsiveness,
lung inflammation and CD4 T-cell Th2 and Th17 phenotype
in both CM and EVs from hMSCs compared with mMSCs;
inhibition of soluble mediators and EVs release reduced the
beneficial effects of all treatments
s Improved survival and reduced lung inflammation,
protein permeability, and bacterial growth
ronchial epithelial cell, CM conditioned medium, DC dendritic cell, EV
factor-1, IL interleukin, KGF keratinocyte growth factor, MSC mesenchymal stem
T-helper
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141) families [59]. Further, incubation of BECs with BALF
EVs from asthmatic patients resulted in increased leuko-
triene and IL-8 release [60].
Additionally, administration of BALF-derived EVs from
mice sensitized and challenged with ovalbumin has been
shown to inhibit IgE response, Th2 cytokine production,
and airway inflammation in experimental asthma [61].
Similar behavior was observed with asthmatic serum-
derived EVs, protecting against allergic airway inflamma-
tion and reducing BALF eosinophil counts, IgE levels, and
Th2 response. EVs from different sources may therefore
play a role in the development of asthma and allergy,
either as a failure to induce effective tolerance or as
enhancers of an already established response. In short,
EVs may be therapeutic targets in anti-allergy treatment.
Recently, the therapeutic effects of EVs derived from
human MSCs (hMSCs) and mouse MSCs (mMSCs)
were investigated in experimental asthma. The authors
observed that systemic administration of EVs from either
hMSCs or mMSCs were each effective – in some cases,
more effective than the administration of hMSCs or
mMSCs themselves – in mitigating allergic airway
hyperresponsiveness and lung inflammation, and altered
the phenotype of antigen-specific CD4 T cells in a model
of severe, acute, mixed Th2/Th17-mediated eosinophilic
and neutrophilic airway allergic inflammation in im-
munocompetent mice. Additionally, blocking EVs release
led to an absence of protective effects associated with
both hMSCs and mMSCs [62].
Pulmonary arterial hypertension
PAH is a disease characterized by hyperplasia and hyper-
trophy of smooth muscle cells in small pulmonary arteries,
associated with an increase in endothelial cell proliferation
that leads to remodeling of pulmonary vessels and, conse-
quently, an increase in mean pulmonary arterial pressure
and right ventricular overload. Data obtained from patients
with PAH show that the severity of PAH is related to an
increase in circulating EVs released from stimulated or
endothelial cells undergoing apoptosis, probably due to
release of soluble vascular cellular adhesion molecule
VCAM-1, and that proinflammatory markers, such as
monocyte chemoattractant protein MCP-1 and highly spe-
cific C-reactive protein, were elevated in PAH patients. In
addition, a further increase in endothelium-derived CD105
microparticles was observed in pulmonary arterial blood
compared with venous blood in patients with PAH [63].
Inflammation plays an important role in the development
of human PAH and there are several animal models of this
condition, such as monocrotaline-induced and hypoxia-
induced PAH in rodents.
Despite significant progress in elucidating PAH patho-
physiology and treatment, few PAH therapies are availableand all have limited effectiveness. Many studies have
therefore investigated the effects of MSC therapy in
PAH, and demonstrated benefit. In a recent investiga-
tion, lung-derived and plasma-derived EVs generated
from monocrotaline-induced PAH led to increased
right ventricular mass and pulmonary vascular wall
thickness, resulting in PAH-like changes in healthy
mice This effect may be promoted directly by EVs on
the pulmonary vasculature or by differentiation of bone
marrow cells to endothelial progenitor cells that induce
pulmonary vascular remodeling [64]. This suggests that
EVs presented altered expressions of miRNAs involved
in pulmonary vascular remodeling. Conversely, in
hypoxia-induced PAH, MSC-derived EVs protected
against elevation of right ventricular systolic pressure
and development of right ventricular hypertrophy,
whereas EVs-depleted medium and fibroblast-derived
EVs had no effect. These beneficial effects of MSC-
derived EVs can be related to suppression of hypoxic
pulmonary macrophage influx and hypoxic activation
of signal transducer and activator of transcription
STAT3, combined with induction of proinflammatory
and proproliferative mediators – including MCP-1 and
hypoxia-inducible mitogenic factor HIMF – and in-
creased pulmonary levels of the key miRNAs miR-17
and miR-204, the expressions of which are reduced in
human pulmonary hypertension [65]. However, the ani-
mal models in which these effects were tested are not
considered good representations of preclinical models
of PAH. The beneficial effects observed with EVs treat-
ment of PAH therefore require more in-depth investi-
gation before they can be considered practice changing.
Acute respiratory distress syndrome
ARDS is a severe clinical condition characterized by
alveolar-capillary damage, accumulation of protein-rich
debris in the alveolar airspace, and progressive respira-
tory failure [66]. Although major improvements in treat-
ment and supportive care of ARDS have been achieved,
its mortality rate remains around 40 % [67].
Recently, some studies reported that MSCs can be a
promising therapeutic approach for ARDS through para-
crine effects [68–70]. Additionally, MSC-derived EVs
have been shown to produce beneficial effects in experi-
mental endotoxin-induced ARDS, reducing lung inflam-
mation [71]. hMSC-derived EVs were therapeutically
effective following Escherichia coli endotoxin-induced
ARDS, thus reducing extravascular lung water, total pro-
tein levels in BALF, edema, and neutrophil infiltration.
These beneficial effects were associated with an increase
in keratinocyte growth factor (KGF) expression, as they
were partially eliminated after delivery of EVs derived
from KGF siRNA-pretreated MSCs [72]. Moreover,
ischemic preconditioning can potentiate the protective
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secretion of exosomes since it confers strong protection
against cell death and promotes their differentiation
potential by activating multiple signaling pathways which
open new avenues for therapeutic approaches [73].
Pneumonia
Bacterial pneumonia is among the main causes of respira-
tory failure in critically ill patients. Despite improvements
in supportive care and appropriate antibiotic use, morbidity
and mortality remain high [74]. Several studies have
reported efficacy of MSCs in preclinical models of pneumo-
nia due to their ability to secrete paracrine factors such as
growth factors, anti-inflammatory cytokines, and antimicro-
bial peptides [75]. Outer-membrane vesicle release is a con-
served phenomenon among pathogenic and nonpathogenic
Gram-negative bacteria [76]. Nevertheless, little is known
regarding Gram-positive EVs, especially their biogenesis
and role in host–pathogen interactions. EVs from Strepto-
coccus pneumonia, one of the leading causes of bacterial
pneumonia worldwide, have only recently been character-
ized [77] and found to exhibit high immunogenicity due to
the presence of the toxin pneumolysin.
Recently, in an in vivo model of E. coli pneumonia in
mice, hMSC-derived EVs were as effective as their par-
ent stem cells in improving survival and mitigating
lung inflammation, protein permeability, and bacterial
growth. The antimicrobial effect of hMSC-derived EVs
was exerted in part through enhancement of monocyte
phagocytosis of bacteria, which could be further
increased by prestimulation of hMSCs with a TLR-3
agonist before EVs release. Uptake of hMSC-derived
EVs through the CD44 receptor into injured human
monocytes and alveolar epithelial cells was critical for
their therapeutic effects. Another factor that should be
stressed is that hMSC-derived EVs decreased tumor
necrosis factor alpha secretion by lipopolysaccharide-
primed human monocytes and restored intracellular
ATP levels in injured human alveolar epithelial type II
cells, suggesting immunomodulatory and metabolomic
effects of EVs. Additionally, administration of a KGF
neutralizing antibody abrogated the survival advantage
mediated by hMSC-derived EVs, suggesting a possible
mechanism for their therapeutic effect [78].
Conclusions
Several studies have reported that MSCs may repair
damaged tissue by modifying target cell function
through paracrine mechanisms without directly re-
placing injured cells. The role of EVs in this mechanism
would be to exchange genetic material, which could
explain the observed phenotypic and functional changes
of MSCs [79]. This genetic material transfer may lead to
the production of soluble factors, thus regulating cellproliferation, apoptosis, and/or inflammation and im-
mune response.
EVs present many advantages over stem cells, such as
homing ability to target tissue, preventing undesired
accumulation in other organs, and absence of any innate
toxicity or association with long-term maldifferentiated
engrafted cells, tumor generation, or immune rejection
after stem cell injection. However, the mechanisms
associated with the beneficial effects induced by MSC-
derived EVs require further investigation. In this line,
the following points in particular warrant better evalu-
ation: which signaling regulates the transfer of biologically
active molecules within EVs, which surface receptors may
yield selective specificity, and which stimuli are respon-
sible for triggering EVs release. Understanding these EVs
mechanisms may allow their use as diagnostic markers,
for the delivery of drugs and genes, and as new thera-
peutic strategies. Although some studies have reported
beneficial effects of MSC-derived EVs in asthma, ARDS,
PAH, and pneumonia, many issues must be addressed
before their use in clinical settings, including: the need for
large-scale EVs production from MSCs; the need for cri-
teria defining the potency of EVs, due to different prepara-
tions and MSC sources; the long-term effects of EVs; and
the biodistribution of EVs in each respiratory disease.
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